Related Experiment Videos
Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer
1Department of Radiation Oncology, First Affiliated Hospital, Medical College of Xi'an Jiaotong University, Xi'an, People's Republic of China.
Background:
MET is involved in the progression of several types of human cancers, while phospho-BAD(Ser-136) is a key molecule in apoptosis and might be regulated by MET. The aim of this study was to investigate the correlation between altered expression of MET and phospho-BAD in non-small cell lung cancer (NSCLC) and their association with clinicopathologic parameters and overall survival.
Methods:
MET and phospho-BAD(Ser-136) proteins were evaluated by immunohistochemical analysis in 183 paraffin-embedded specimens and were also assessed by Western blotting analysis in 12 frozen tumor tissue samples, which were representative examples of immunohistochemical staining.
Results:
Positive expression of MET and phospho-BAD(Ser-136) occurred in 67.2% and 49.2% of the 183 cases of NSCLC, respectively. However, neither MET expression nor phospho-BAD(Ser-136) expression was associated with any clinicopathologic parameter. A significant correlation was found between MET and phospho-BAD(Ser-136) expression levels evaluated by immunohistochemistry (r = 0.268, P < 0.001). Overexpression of MET was significantly associated with shortened overall survival in univariate analysis (P < 0.001). Moreover, patients with a MET+/phospho-BAD(Ser-136)+ phenotype had a poorer prognosis than others (P < 0.001). Multivariate Cox proportional hazard analysis confirmed that MET expression is a prognostic factor for NSCLC.
Conclusion:
MET expression might be correlated with phospho-BAD(Ser-136) expression, and may be an adverse predictor for NSCLC. Activation of the MET/phospho-BAD(Ser-136) signaling pathway might play a role in the development and progression of NSCLC.
Insights
MET and phospho-BAD(Ser-136) expression correlates in non-small cell lung cancer (NSCLC). MET overexpression is linked to poorer survival, suggesting MET/phospho-BAD(Ser-136) pathway activation in NSCLC progression.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- MET signaling is implicated in human cancer progression.
- Phospho-BAD(Ser-136) is crucial for apoptosis and may be regulated by MET.
- Investigating MET and phospho-BAD(Ser-136) in non-small cell lung cancer (NSCLC) is important.
Purpose of the Study:
- To explore the correlation between MET and phospho-BAD(Ser-136) expression in NSCLC.
- To assess the association of MET and phospho-BAD(Ser-136) with clinicopathologic parameters.
- To determine their impact on overall survival in NSCLC patients.
Main Methods:
- Immunohistochemical analysis of MET and phospho-BAD(Ser-136) in 183 NSCLC specimens.
- Western blotting analysis of MET and phospho-BAD(Ser-136) in 12 frozen tumor samples.
- Correlation analysis with clinicopathologic parameters and survival data.
Main Results:
- MET and phospho-BAD(Ser-136) were expressed in 67.2% and 49.2% of NSCLC cases, respectively.
- A significant positive correlation (r = 0.268, P < 0.001) was observed between MET and phospho-BAD(Ser-136) expression.
- MET overexpression correlated with significantly shortened overall survival (P < 0.001), and MET expression was confirmed as a prognostic factor.
Conclusions:
- MET expression may correlate with phospho-BAD(Ser-136) expression in NSCLC.
- MET appears to be an adverse prognostic predictor in NSCLC.
- Activation of the MET/phospho-BAD(Ser-136) pathway may contribute to NSCLC development and progression.
